NURS 5334 FINAL PAPER 2026 FULL
QUESTIONS AND CORRECT ANSWERS
◉ Selecting a Birth Control Method.
Answer: Consider effectiveness, safety, personal preference
◉ Oral Contraceptives.
Answer: MOA—inhibit ovulation
Classification (two main categories)
Combination oral contraceptives (OCs)
Estrogen and progestin
Progestin-only OCs ('mini-pills')
Three major subgroups of combination OCs
Monophasic
Biphasic
Triphasic
◉ Estrogens and Progesterone in OCPs.
Answer: Estrogens—ethinyl, estradiol, estriol and estradiol valerate
Progesterone—4 generations
1st generation—ethynodiol diacetate and norethindrone
,2nd gen—levonorgestrel and norgestrel
3rd gen—desogestrel and norgestimate
4th gen—dienogest and drospirenone
◉ Combination Oral Contraceptives.
Answer: Adverse effects
Noncontraceptive uses
Drugs that reduce the effects
Drugs whose effects are decreased by OCs
Drugs whose effects are increased by OCs
Unique properties of Beyaz and Safyral? Natazia
Thyrombolytic disorders
Increase risk—heavy smoking, a history of thrombo embolism,
thrombophilias
Hypertension
Cancer
Stroke in patients with migraine
Teratogenic effects
Abnormal uterine bleeding
Use in pregnancy and lactation
Benign hepatic adenoma
Glucose intolerance
, Decrease risks of ovarian cancer, endometrial cancer, ovarian cysts,
pelvic inflammatory disease, benign breast disease, iron deficiency
anemia, and acne
Favorable effect on menstrual cycles
Diminished cramps; lighter, shorter, more predictable flow
Rifampin
Ritonavir
Antiepileptic drugs
St. John's wort
Warfarin
Insulin
Oral hypoglycemics
Several agents, including theophylline, tricyclic antidepressants,
diazepam, and chlordiazepoxide
Beyaz and Safyral
Contain levomefolate (metabolite of folic acid)
Reduce risk for fetal neural tube defects and spinal bifida, if
pregnancy should occur despite contraceptive use
Natazia
Estradiol valerate—prodrug that undergoes rapid conversion to
estradiol, does not cause potassium retention
Dienogest—fourth gen progestin
QUESTIONS AND CORRECT ANSWERS
◉ Selecting a Birth Control Method.
Answer: Consider effectiveness, safety, personal preference
◉ Oral Contraceptives.
Answer: MOA—inhibit ovulation
Classification (two main categories)
Combination oral contraceptives (OCs)
Estrogen and progestin
Progestin-only OCs ('mini-pills')
Three major subgroups of combination OCs
Monophasic
Biphasic
Triphasic
◉ Estrogens and Progesterone in OCPs.
Answer: Estrogens—ethinyl, estradiol, estriol and estradiol valerate
Progesterone—4 generations
1st generation—ethynodiol diacetate and norethindrone
,2nd gen—levonorgestrel and norgestrel
3rd gen—desogestrel and norgestimate
4th gen—dienogest and drospirenone
◉ Combination Oral Contraceptives.
Answer: Adverse effects
Noncontraceptive uses
Drugs that reduce the effects
Drugs whose effects are decreased by OCs
Drugs whose effects are increased by OCs
Unique properties of Beyaz and Safyral? Natazia
Thyrombolytic disorders
Increase risk—heavy smoking, a history of thrombo embolism,
thrombophilias
Hypertension
Cancer
Stroke in patients with migraine
Teratogenic effects
Abnormal uterine bleeding
Use in pregnancy and lactation
Benign hepatic adenoma
Glucose intolerance
, Decrease risks of ovarian cancer, endometrial cancer, ovarian cysts,
pelvic inflammatory disease, benign breast disease, iron deficiency
anemia, and acne
Favorable effect on menstrual cycles
Diminished cramps; lighter, shorter, more predictable flow
Rifampin
Ritonavir
Antiepileptic drugs
St. John's wort
Warfarin
Insulin
Oral hypoglycemics
Several agents, including theophylline, tricyclic antidepressants,
diazepam, and chlordiazepoxide
Beyaz and Safyral
Contain levomefolate (metabolite of folic acid)
Reduce risk for fetal neural tube defects and spinal bifida, if
pregnancy should occur despite contraceptive use
Natazia
Estradiol valerate—prodrug that undergoes rapid conversion to
estradiol, does not cause potassium retention
Dienogest—fourth gen progestin
